A New Direction in Liquid Biopsy
When Syantra Inc. announced new patent filings on May 22, 2025, it signaled an ambitious expansion of its cancer detection platform into uncharted territory. The privately held Calgary-based biotech—known for a blood test that catches early breast cancers by reading mRNA signals—has long “flipped the script” on liquid biopsies by not hunting for tumor DNA fragments like most rivals. Instead, Syantra’s Onco-ID™ platform listens to the body’s own immune response for the subtlest hints of disease. Now, armed with fresh intellectual property, Syantra is moving beyond detection into intervention. Its latest patents extend “previous work in cancer molecular diagnostics to encompass new drug targets and therapeutics”.
